Mastitis (Lactational & Non-Lactational) Treatment
Covered by Aetna in California

Dicloxacillin 500mg four times daily × 10–14 days (first-line per Academy of Breastfeeding Medicine 2022 Protocol and StatPearls/NIH mastitis guidelines — targets Staphylococcus aureus, the predominant pathogen in lactational mastitis). Safe for breastfeeding; minimal transfer to breast milk. Take on empty stomach for optimal absorption. Continue frequent breastfeeding or pumping throughout treatment to prevent milk stasis progression.

Cephalexin 500mg four times daily × 10–14 days — equivalent first-line option, somewhat better GI tolerability than dicloxacillin; safe during breastfeeding. For penicillin-allergic patients: clindamycin 300mg four times daily × 10–14 days (note C. difficile risk — use only for confirmed penicillin allergy). TMP-SMX DS twice daily × 10–14 days for MRSA-suspected mastitis (prior MRSA history, CA-MRSA community prevalence, no improvement on first-line therapy after 48–72 hours) — NOT used in pregnancy or for infants <2 months. NSAIDs (ibuprofen 400–600mg every 6–8 hours) for pain and inflammation regardless of antibiotic choice.

Dicloxacillin and cephalexin are Tier 1 generics on Aetna CA formulary, typically $4–$15 for a 10-day supply. Clindamycin is also Tier 1 (typically $10–$20). TMP-SMX DS is Tier 1, typically $4–$10. No PA required for any of these agents.

Per ABM Protocol #36 (2022) and NIH/StatPearls guidelines, antibiotics are indicated when mastitis symptoms (localized tenderness, erythema, warmth) do not improve after 12–24 hours of conservative measures (continued breastfeeding, ibuprofen, warm compresses), or when systemic signs are present (fever ≥38°C/100.4°F, flu-like symptoms, tachycardia). Prophylactic antibiotics are NOT recommended. Breastfeeding should continue throughout treatment — discontinuing feeds worsens milk stasis and increases abscess risk. If no improvement within 48 hours on first-line antibiotics, a milk culture and breast ultrasound to rule out abscess are recommended. Abscess = in-person care (aspiration or incision and drainage). Non-lactating women presenting with unilateral breast erythema, mass, and nipple changes require urgent evaluation for inflammatory breast carcinoma (IBC) — a rare but aggressive malignancy that can mimic mastitis clinically.

Yes, and it is strongly recommended. Continuing to breastfeed — or pump if nursing is too painful — is a critical part of mastitis treatment. Milk stasis is the primary driver of bacterial growth in the breast; stopping feeds increases the risk of milk buildup, worsening pain, and progression to a breast abscess. Both dicloxacillin and cephalexin (the first-line antibiotics for mastitis) transfer minimally to breast milk and are considered compatible with breastfeeding by the American Academy of Pediatrics and the Academy of Breastfeeding Medicine. Your infant receives a negligible antibiotic dose through breast milk at standard maternal doses.

Contact TDMD immediately for a follow-up visit. Lack of improvement within 48–72 hours on appropriate antibiotics suggests one of three possibilities: MRSA infection (requiring a switch to TMP-SMX or clindamycin), breast abscess formation (requiring in-person ultrasound-guided aspiration or surgical drainage — antibiotics alone cannot treat a formed abscess), or a non-infectious cause (rare inflammatory conditions). Dr. Bhavsar will evaluate for abscess risk and, if suspected, provide an urgent referral for breast ultrasound imaging. Do not wait it out beyond 48–72 hours without reassessment — abscess formation is preventable with timely escalation of treatment.

Possibly, but with important caveats. Non-lactational breast erythema and swelling can have multiple causes — periductal mastitis (often associated with smoking), skin infection (cellulitis), or, critically, inflammatory breast carcinoma (IBC). IBC is a rare but aggressive breast cancer that classically presents with rapid-onset breast erythema, skin thickening ('peau d'orange'), warmth, and swelling — closely mimicking mastitis — and can lack a distinct palpable lump. Unlike infectious mastitis, IBC does not respond to antibiotics. For non-lactating women, TDMD conducts a careful video assessment for IBC warning signs and, when present, provides an urgent referral for in-person breast imaging (mammogram + ultrasound) and surgical oncology consultation. Any non-lactating woman with persistent or non-responding breast erythema needs in-person evaluation and breast imaging; this is not a condition that should be managed with antibiotics alone via telehealth.

Yes. Aetna commercial plans cover telehealth visits for Mastitis (Lactational & Non-Lactational) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your mastitis treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your mastitis treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.